

 WILEY

PERSPECTIVES IN MOLECULAR TOXINOLOGY



Edited by
André Ménez

CONTENTS

List of Contributors xix

Preface xxix

I TOXINS FROM MICROORGANISMS 1

1 Bacterial Toxins with Metalloprotease Activity 3

O. Rossetto and C. Montecucco

1.1 Introduction 3

1.2 Tetanus and botulinum neurotoxins 4

1.2.1 Introduction 4

1.2.2 Genetics and structure 4

1.2.3 Neuronal intoxication 7

1.3 The anthrax lethal factor 10

1.3.1 Introduction 10

1.3.2 The protective antigen PA and toxin internalisation and translocation 10

1.3.3 The metalloproteolytic activity of the lethal factor LF 12

1.4 Fragilysins from *Bacteroides fragilis* 13

1.4.1 Introduction 13

1.4.2 Genetics and structure of fragilysin (BFT) 13

1.4.3 The metalloproteolytic activity of fragilysin 15

Acknowledgements 17

References 17

2 The Cholesterol-dependent Cytolysins: Current Perspectives on Membrane Assembly and Insertion 23

E. Hotze and R.K. Tweten

2.1 Introduction 23

2.2 CDC structure 24

2.3 Membrane recognition 25

2.3.1 Domain 4 25

2.3.2 Cellular recognition 26

2.4	Formation of oligomeric complexes and insertion of the transmembrane domains	28
2.4.1	Identification of the transmembrane domain of PFO	28
2.4.2	Oligomer assembly and insertion	29
2.5	The role of the CDCs in bacterial pathogenesis	31
2.5.1	Listeriolysin O	32
2.5.2	Pneumolysin	33
2.5.3	Perfringolysin O	33
2.5.4	Streptolysin O	33
2.6	Summary and perspectives	34
	References	35
3	Toxin-producing Dinoflagellates	39
	<i>M.J. Holmes and R. Lewis</i>	
3.1	Review of toxin-producing dinoflagellates	45
3.1.1	Dinoflagellates with motile cell predominantly planktonic	45
3.1.2	Dinoflagellates with motile cell predominantly benthic	50
	References	55
4	Involvement of Na⁺ in the Actions of Ciguatoxins and Brevetoxins that Stimulate Neurotransmitter Release and Affect Synaptic Transmission	67
	<i>J. Molgó and E. Benoit</i>	
4.1	Introduction	67
4.2	Origins and chemical structures of ciguatoxins and brevetoxins	68
4.3	Voltage-dependent Na ⁺ channels as targets for ciguatoxins and brevetoxins	72
4.4	Alterations of neuronal Na ⁺ current and membrane potential by ciguatoxins and brevetoxins	73
4.5	Ciguatoxin- and brevetoxin-mediated swelling of the nodes of Ranvier of myelinated axons	75
4.6	Ciguatoxins and brevetoxins increase intracellular Ca ²⁺ levels in neuronal cells	77
4.7	Quantal transmitter release changes caused by ciguatoxins and brevetoxins	78
4.7.1	Synchronous evoked quantal transmitter release	79
4.7.2	Asynchronous quantal transmitter release	80
4.8	Swelling of motor nerve terminals <i>in situ</i>	82
4.9	Impairment of synaptic vesicle recycling by ciguatoxins and brevetoxins	83

4.10 Perspectives	86
Acknowledgements	87
References	87

II ANIMAL TOXINS AND NEW METHODOLOGIES 95

5 Role of Discovery Science in Toxicology: Examples in Venom Proteomics 97

J.W. Fox, J.D. Shannon, B. Stefansson, A.S. Kamiguti, R.D.G. Theakston, S.M.T. Serrano, A.C.M. Camargo and N. Sherman

5.1 Introduction	97
5.2 2-D gel electrophoresis/proteome analysis of snake venoms	98
5.2.1 <i>Dispholidus typus</i> (Boomslang) proteome	99
5.3 Proteomic comparison of the venoms from two different snake species producing similar pathologies of envenoming	100
5.4 Use of different pI ranges for venom 2-D PAGE proteome analysis	102
5.5 Proteome comparison of venoms from identical snake species	102
References	105

6 Proteomics of Venom Peptides 107

R. Stöcklin and P. Favreau

6.1 Proteomics	107
6.2 Mass spectrometry	108
6.2.1 Ion sources	109
6.2.2 Mass analysers	109
6.2.3 Mass spectrometers	110
6.3 Animal venom proteomics	111
6.3.1 Proteomic strategies	112
6.3.2 Direct analysis of crude venoms	113
6.3.3 Identification and characterisation of isolated toxins	114
6.3.4 On-line LC-ES-MS of crude <i>Apis mellifera</i> (honey bee) venom	114
6.3.5 MALDI-TOF-MS analysis of crude venoms	115
6.3.6 Proteomics of <i>Conus</i> venom	117
6.3.7 Discovery of novel sarafotoxins in <i>Atractaspis</i> snake venoms	119
6.4 Conclusion	119
Acknowledgements	121
References	121

7	High-resolution NMR of Venom Toxins in Nanomolar Amounts	125
	<i>M. Delepierre</i>	
7.1	Introduction	125
7.2	Structural characterisation by NMR using small amounts of material	126
7.2.1	The signal-to-noise ratio	127
7.2.2	Small-volume probes	127
7.3	Nano.nmr probe applications	133
7.4	Conclusions	135
	Acknowledgements	136
	References	136

III ANIMAL TOXINS: FROM FUNDAMENTAL STUDIES TO DRUGS? 141

8	Cone Snails and Conotoxins Evolving Sophisticated Neuropharmacology	143
	<i>B.M. Olivera, J.S. Imperial and G Bulaj</i>	
8.1	<i>Conus</i> venoms: the molecules	143
8.1.1	Overview	143
8.1.2	Post-translational modification of conopeptides	144
8.1.3	Biosynthesis of conopeptides	144
8.1.4	Functional domains of conopeptide precursors: the generation of molecular diversity	146
8.1.5	Perspectives	147
8.2	Conopeptides: functional aspects	147
8.2.1	Overview	147
8.2.2	Biology of cone snails: a synopsis	148
8.2.3	Molecular mechanisms	148
8.2.4	Toxin cabals	149
8.2.5	Interspecific divergence: an overview	151
8.3	Conopeptides in medicine and neuroscience	152
8.3.1	Introduction	152
8.3.2	Medical applications	152
8.3.3	<i>Conus</i> venoms: a toolbox for the neuroscientist	153
8.4	Future directions	153
8.4.1	Introduction	153
8.4.2	Structure and folding	154
8.4.3	Delivery design and post-translational modification	155
8.4.4	<i>In vitro</i> extension of peptide evolution: drug development	156
	Acknowledgements	156
	References	156

9 Toxin Structure and Function: What Does Structural Genomics Have To Offer? 159

R.S. Norton

- 9.1 Many functions but few folds 159
- 9.2 Structural genomics 161
- 9.3 Membrane proteins: a major challenge 164
- 9.4 Does protein structure explain function? 167
- 9.5 Future prospects 168
- Acknowledgements 169
- References 169

10 The Binding Sites of Animal Toxins Involve Two Components: A Clue for Selectivity, Evolution and Design of Proteins? 175

A. Ménez, D. Servent and S. Gasparini

- 10.1 Introduction 175
- 10.2 On the molecular targets 176
 - 10.2.1 The voltage-gated potassium channels 176
 - 10.2.2 The nicotinic acetylcholine receptors (AChRs) 177
- 10.3 On the binding sites displayed by animal toxins 178
- 10.4 What can we learn from comparisons of binding sites displayed by animal toxins? 178
 - 10.4.1 An understanding of the structural basis for the biological diversity of animal toxins: one mould for multiple missions 178
 - 10.4.2 A molecular rationale for the pleiotropic properties of animal toxins 179
- 10.5 How do binding site properties help to understand the evolution of animal toxins? 188
- 10.6 Design of novel toxins 189
 - 10.6.1 Modulating the original specificity profiles of natural toxins 189
 - 10.6.2 Design of novel functions on toxin folds 190
- 10.7 Conclusions 191
- Acknowledgements 191
- References 191

11 Scorpion Genes and Peptides Specific for Potassium Channels: Structure, Function and Evolution 201

L.D. Possani, E. Merino, M. Corona and B. Becerril

- 11.1 Introduction 201
- 11.2 Isolation and primary sequences 202

11.3	Three-dimensional characterisation	204
11.4	Physiological effects	205
11.5	Structure of genes encoding K ⁺ -peptides	207
11.6	Phylogenetic tree and evolution	208
11.7	Perspectives and concluding remarks	209
	Acknowledgements	211
	References	211

12 Scorpion Toxins Differentiating among Neuronal Sodium Channel Subtypes: Nature's Guide for Design of Selective Drugs 215

D. Gordon, N. Gilles, D. Bertrand, J. Molgó, G.M. Nicholson, M.P. Sauviat, E. Benoit, I. Shichor, I. Lotan, M. Gurevitz, R.G. Kallen and S.H. Heinemann

12.1	Introduction	215
12.1.1	Mammalian excitable tissues display different sodium channel subtypes	216
12.1.2	Scorpion toxins affecting sodium channels	216
12.2	Scorpion α -toxins and receptor site-3 on sodium channel subtypes	218
12.2.1	Localisation of receptor site-3 on the sodium channel	219
12.3	Selective interaction of α -toxins with distinct mammalian sodium channel subtypes	219
12.3.1	Differences in toxicity of α -toxins in CNS and periphery	219
12.3.2	α -Toxins differentiate between neuronal sodium channel subtypes in CNS	221
12.3.3	Difference in sub-cellular localisation of Lqh-II and Lqh-III sodium channel targets	223
12.3.4	Effects of scorpion α -toxins on peripheral sodium channels	224
12.3.5	Sodium channels of similar tissues differ in various vertebrates	225
12.4	Do the various α -toxins interact identically with receptor site-3?	225
12.5	Scorpion β -toxins that bind to receptor site-4	227
12.5.1	Excitatory and depressant toxins exclusively bind to insect sodium channels	227
12.5.2	Localisation of receptor site-4 on the sodium channel	229
12.6	Sodium channel domain-2 confers selective binding of excitatory toxins	230

- 12.7 Concluding remarks and perspectives 230
 - 12.7.1 Structural differences at the toxin–receptor interacting surfaces of various sodium channels 230
 - 12.7.2 Selective recognition 231
- References 232

13 Diversification of Toxic Sites on a Conserved Protein Scaffold – a Scorpion Recipe for Survival 239

M. Gurevitz, N. Zilberberg, O. Froy, M. Turkov, R. Wilunsky, I. Karbat, J. Anglister, B. Shaanan, M. Pelhate, M.E. Adams, N. Gilles and D. Gordon

- 13.1 Diverse pharmacology of scorpion toxins affecting sodium channels 239
- 13.2 Structure–activity relationship 240
 - 13.2.1 Cloning and functional expression 240
 - 13.2.2 Determination of three-dimensional structures 240
 - 13.2.3 Elucidation of bioactive surfaces 242
- 13.3 Diversification of toxins 243
 - 13.3.1 Convergent and divergent toxin evolution 243
 - 13.3.2 Scorpion toxin gene families and genomic organisation 244
 - 13.3.3 A putative mechanism for diversification of bioactive surfaces in scorpion ‘long’ toxins 245
- 13.4 Perspectives in toxin design 246
 - 13.4.1 Mobilisation of bioactive sites on a conserved scaffold 246
 - 13.4.2 Future prospects in design of target-selective toxins 247

Acknowledgements 248

References 248

14 Methodological Approaches to the Study of Ion Channels Using Peptide Toxins: Proposed Comprehensive Guidelines 255

M. De Waard, J.-M. Sabatier and H. Rochat

- 14.1 Ion channels are important targets for pharmacological and therapeutic interventions 256
- 14.2 Toxins as molecular traces for the purification of cloned ion channels 257
- 14.3 On the search for new natural ligands acting on ion channels 258
 - 14.3.1 Biological sources for novel compounds acting on ion channels 258
 - 14.3.2 Toxin screening tests 259
 - 14.3.3 Production of toxins 261

14.4	Strategies in the design of therapeutically active molecules	263
14.5	Structure–function relationship approach for the design of novel therapeutic agents	263
14.5.1	Toxin and ion channel structure	263
14.5.2	Design of novel compounds	264
14.6	Conclusion	266
	References	267
15	Toxins as Probes for Structure and Specificity of Synaptic Target Proteins	271
	<i>P. Taylor, B. Molles, S. Malany and H. Osaka</i>	
15.1	Introduction	271
15.2	Site selectivity of the toxins	273
15.3	Towards a structure of the subunit binding face	276
15.4	Delineation of individual residue contributions to the binding energy	276
15.5	Concluding remarks	278
	References	278
16	Allosteric and Steric interactions of Polyamines and Polyamine-containing Toxins with Nicotinic Acetylcholine Receptors	281
	<i>T.J. Brier, I.R. Mellor and P.N.R. Usherwood</i>	
16.1	Introduction	281
16.2	Electrophysiological studies	284
16.2.1	Potentiation	284
16.2.2	Inhibition	284
16.2.3	Ligand-binding studies	290
16.2.4	Photoaffinity labelling experiments	290
16.3	Discussion	292
	References	293
17	Anabaseine as a Molecular Model for Design of $\alpha 7$ Nicotinic Receptor Agonist Drugs	297
	<i>W.R. Kem</i>	
17.1	Introduction	297
17.2	Neuronal nicotinic receptors as drug targets	299
17.3	Anabaseine, a natural toxin	300
17.4	Benzyldine and cinnamylidene derivatives of anabaseine	303
17.5	<i>In vitro</i> studies of DMXBA interaction with nicotinic receptors	303
17.6	DMXBA interaction with other receptors	305
17.7	Effects of DMXBA on cognition and sensory gating	306
17.8	Effects of DMXBA upon other neurotransmitter systems	306
17.9	Neuroprotective actions	307

17.10	Pharmacokinetics and biotransformation of DMXBA	307
17.11	Effects of chronic nicotinic agonist administration	308
17.12	Nicotine dependence	308
17.13	Other compounds acting on $\alpha 7$ receptors	309
17.14	Possible toxic consequences of excessive $\alpha 7$ receptor stimulation	309
17.15	Concluding comments	310
	Acknowledgements	310
	References	311
18	Understanding the Structure-Function Relationship of Snake Venom Cardiotoxins	315
	<i>T.K.S. Kumar, S. Srisailam, R.R. Vethanayagam and C. Yu</i>	
18.1	Introduction	315
18.2	The chemistry of cardiotoxins	315
18.3	Structure of cardiotoxins	316
18.4	Mode of action of cardiotoxins	321
18.5	Is there a receptor for cardiotoxins?	323
	Acknowledgements	324
	References	324
19	Structure and Function of Disintegrins and C-lectins: Viper Venom Proteins Modulating Cell Adhesion	327
	<i>S. Niewiarowski, C. Marcinkiewicz, I. Wierzbicka-Patynowski, M.A. McLane and J.J. Calvete</i>	
19.1	Introduction	327
19.2	Viper venom anti-adhesive molecules	328
19.3	Monomeric disintegrins	328
19.4	Dimeric disintegrins	330
19.5	C-lectin-like proteins	333
19.6	Implication in biomedical research	335
	References	337
20	Prothrombin Activators from Snake Venoms	341
	<i>R.M. Kini, J.S. Joseph and V.S. Rao</i>	
20.1	Introduction	341
20.2	Group A prothrombin activators	342
20.3	Group B prothrombin activators	342
20.4	Group C prothrombin activators	344
20.5	Group D prothrombin activators	345
20.6	Implications of structural studies of prothrombin activators	348
20.7	Physiological role of prothrombin activators	349
	Acknowledgements	351
	References	351

21 C-type Lectins from Snake Venoms: New Tools for Research in Thrombosis and Haemostasis 357

A. Wisner, M. Leduc and C. Bon

21.1 Introduction 357

21.2 Snake venom CTL affecting platelet functions 362

21.2.1 Interaction of snake venom CTLs with platelet GPIb 363

21.2.2 Snake venom CTLs interacting with vWF 365

21.2.3 Snake venom CTL interacting with the collagen receptor GPVI 366

21.3 Snake venom CTLs affecting blood clotting 366

21.3.1 Snake venom CTLs with anti-coagulant activity 366

21.3.2 Snake venom CTLs with pro-coagulant activity 367

21.4 Conclusion 368

References 369

22 Toxins Leading to Medicines 377

A.L. Harvey

22.1 Introduction 377

22.2 Neuromuscular blocking agents 377

22.3 Analgesic effects of ω -conotoxins and their analogues 378

22.4 Conantokins as potential anti-epileptic drugs 379

22.5 From arrow-poison to analgesic 380

22.6 Leads from scorpion toxins 380

22.7 Anti-platelet agents from snake venoms 381

22.8 Hypoglycaemics from Gila monster venom 381

References 382

IV EVOLUTION OF ANIMAL TOXINS 385

23 Accelerated and Regional Evolution of Snake Venom Gland Isozymes 387

23.1 Association of accelerated evolution with functional diversities in snake venom isozymes 387

23.1.1 Structures of PLA₂ isozymes from the venoms of *Trimeresurus* snakes 387

23.1.2 Diverse physiological functions of PLA₂ isozymes from *T. flavoviridis* venom 389

23.1.3 Structures of the cDNA and genes encoding *Trimeresurus* venom-gland PLA₂ isozymes 390

23.1.4 Accelerated evolution of venom-gland PLA₂ isozymes of *Trimeresurus* snakes 391

23.1.5 Mechanism of accelerated evolution in snake venom-gland PLA₂ isozyme genes 392

- 23.1.6 Evolution of *T. flavoviridis* serum inhibitors against its venom PLA₂s 394
- 23.2 Regional evolution of venom-gland PLA₂ isozymes of *T. flavoviridis* snakes 395
 - 23.2.1 Distribution of *T. flavoviridis* snakes 395
 - 23.2.2 Regional differences in evolution of venom PLA₂ isozymes 396
- 23.3 Problems in the future 397
- References 398

24 Functional Diversification of Animal Toxins by Adaptive Evolution 401

D. Kordis, I. Križaj and F. Gubenšek

- 24.1 Introduction 401
- 24.2 Biological roles of venoms 401
- 24.3 Toxins belong to different classes of proteins 402
- 24.4 Toxins have many molecular targets 404
 - 24.4.1 Ion channels 404
 - 24.4.2 Voltage-activated ion channels 404
 - 24.4.3 Ligand-gated ion channels 406
 - 24.4.4 Ca²⁺-binding proteins 406
 - 24.4.5 Pentraxins 406
 - 24.4.6 Lectins 407
 - 24.4.7 Other targets 407
 - 24.4.8 Targeting of toxins to receptor subtypes 407
 - 24.4.9 Synergistic action of multiple toxins 407
- 24.5 Toxins are members of large multigene families 408
- 24.6 Adaptive evolution of animal toxins 409
 - 24.6.1 Evolution of new functions by gene duplication 409
 - 24.6.2 Introns in toxin multigene families are highly conserved 411
 - 24.6.3 Very high evolutionary rate of toxins 411
 - 24.6.4 Adaptive evolution diversifies different regions of toxins 412
 - 24.6.5 What is the driving force for the adaptive evolution of toxins? 412
 - 24.6.6 Mechanisms for evolving hypervariability of animal toxins 412
- 24.7 Extreme structural plasticity of toxins 413
- Acknowledgements 415
- References 415

V FROM VENOMS TO TREATMENT 421**25 The Venomous Function 423***M. Goyffon*

- 25.1 Venomous apparatus 423
 - 25.1.1 Venomous glands 424
 - 25.1.2 Injecting apparatus 425
- 25.2 Venoms: modes of action and composition 425
- 25.3 Venoms and molecular evolution 427
 - 25.3.1 vPLA₂s 427
 - 25.3.2 Toxins of Buthid scorpion venoms 428
- 25.4 Venoms and vital functions 429
- 25.5 Venoms and envenomations 429
- 25.6 Conclusion 431
- Acknowledgements 432
- References 432

26 Are Inhibitors of Metalloproteinases, Phospholipases A₂ and Myotoxins Members of the Innate System? 435*J. Perales and G.B. Domont*

- 26.1 Introduction 435
- 26.2 Snake venom metalloproteinases (SVMPs) 436
- 26.3 Snake venom metalloproteinase inhibitors (SVMPIs) 437
 - 26.3.1 Classification 437
 - 26.3.2 High molecular mass class 437
 - 26.3.3 Low molecular mass class 440
 - 26.3.4 Genic family 440
 - 26.3.5 Mechanisms of inhibition 441
- 26.4 Phospholipases A₂ (PLA₂s) and their receptors 442
- 26.5 PLA₂ inhibitors (PLIs): antineurotoxic and antimyotic 443
 - 26.5.1 Classification 443
 - 26.5.2 Specificity 444
 - 26.5.3 Mechanism 447
 - 26.5.4 Inhibitors of snake venom PLA₂s toxic effects 448
- 26.6 Perspectives 449
- 26.7 Finally, an answer to the title 451
- Acknowledgements 452
- References 452

27	The Treatment of Snake Bites: Analysis of Requirements and Assessment of Therapeutic Efficacy in Tropical Africa	457
	<i>J.-P. Chippaux</i>	
27.1	Introduction	457
27.2	Analysis of requirements	459
27.2.1	Actual level of health: incidence, morbidity and lethality	459
27.2.2	Desirable levels of health: a difficult parameter to assess	464
27.3	Analysis of supply	464
27.3.1	Producers	464
27.3.2	Prescribers	465
27.4	Analysis of consumption	466
27.4.1	The decision to undergo treatment	466
27.4.2	Access to care	467
27.4.3	Staff training	467
27.5	Solutions	468
27.5.1	Improved identification of requirement	468
27.5.2	Improving supply	468
27.6	Conclusions	471
	References	471